FDA Authorizes Bivalent Booster for Children
Update: Oct 17-28, 2022
On October 12, the U.S. Food and Drug Administration (FDA) amended the emergency use authorizations of the two bivalent COVID-19 vaccines authorizing their use in younger age groups. Children as young as five years are now eligible to receive the bivalent boosters two months following completion of any FDA-approved or authorized monovalent primary series or monovalent booster vaccination.
The primary series vaccine or initial booster dose previously administered does not impact the effectiveness of either bivalent booster. Additionally, the FDA has authorized the mix-and-match of COVID-19 boosters with the primary series vaccine.
In related news, on October 13, the U.S. Department of Health and Human Services (HHS) issued another 90-day public health emergency declaration. This will be the eleventh time since the first declaration in January 2020. The current extension ends on January 11, 2023. According to the Centers for Disease Control (CDC), the number of new COVID-19 cases daily is more than 38,000, with 328 deaths daily.